Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Guanfacine
Drug ID BADD_D01046
Description Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD.[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274]
Indications and Usage Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.[L11277]
Marketing Status approved; investigational
ATC Code C02AC02
DrugBank ID DB01018
KEGG ID D08031
MeSH ID D016316
PubChem ID 3519
TTD Drug ID Not Available
NDC Product Code 0591-0444; 0591-0453; 27241-243; 42291-326; 60505-3928; 62135-728; 70436-040; 72162-2029; 16714-191; 16714-192; 42806-296; 60429-960; 70436-042; 71205-946; 0228-2855; 53746-711; 60505-3929; 60505-3930; 63629-1102; 63629-8203; 70518-1369; 71205-945; 63304-927; 65162-713; 70436-039; 70518-2771; 24658-730; 24979-198; 0228-2851; 63629-1105; 16714-190; 16714-193; 24979-538; 60429-961; 62135-727; 63629-8161; 70518-1371; 71205-947; 24979-199; 24979-536; 50268-374; 63304-926; 24658-731; 42806-048; 53746-713; 54092-515; 60429-962; 60429-963; 60505-3927; 63629-1103; 65162-711; 70436-041; 71335-9750; 72162-2030; 42291-327; 0228-2850; 0228-2853; 54092-517; 63187-302; 63304-924; 63304-925; 71205-944; 24979-534; 27241-242; 42291-325; 50090-5991; 54092-519; 63629-1104; 68094-065; 70518-0793; 0904-7140; 24979-533; 42291-324; 50090-6073; 50090-6493; 54092-513
UNII 30OMY4G3MK
Synonyms Guanfacine | Tenex | Guanfacine Hydrochloride | Hydrochloride, Guanfacine | Guanfacine Monohydrochloride | Monohydrochloride, Guanfacine | Lon798 | BS-100-141 | BS 100 141 | BS100141 | Estulic
Chemical Information
Molecular Formula C9H9Cl2N3O
CAS Registry Number 29110-47-2
SMILES C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Presyncope02.11.04.013; 17.02.05.009; 24.06.02.0100.000173%
Pruritus23.03.12.001--
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.001816%Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.0030.000727%
Rash23.03.13.001--Not Available
Raynaud's phenomenon24.04.03.0030.002439%Not Available
Retching07.01.07.0020.000173%Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Screaming19.04.02.020; 08.01.03.0990.000588%Not Available
Sedation17.02.04.0050.000848%Not Available
Seizure17.12.03.0010.001211%
Shock24.06.02.0020.000173%Not Available
Sinus arrhythmia02.03.03.008--Not Available
Sinus bradycardia02.03.03.0090.000259%
Skin discolouration23.03.03.0050.000381%Not Available
Skin exfoliation23.03.07.003--Not Available
Sleep disorder19.02.04.0010.000381%Not Available
Sleep terror19.02.03.008; 17.15.02.0060.000381%Not Available
Somnolence17.02.04.006; 19.02.05.0030.005639%
Suicidal ideation19.12.01.0030.001643%
Suicide attempt19.12.01.0040.000259%
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.001937%
Tachycardia02.03.02.0070.000346%Not Available
Tension19.06.02.005--Not Available
Testicular disorder21.13.01.002--
Thirst14.03.02.007; 08.01.09.0210.000640%Not Available
Tic19.11.04.001; 17.02.05.0240.000259%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000173%
Tremor17.01.06.0020.000467%
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages